Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
- Japan to Increase Reimbursement Rounds to 7 Times a Year from 2025
May 16, 2024
- Alexion Takes Hit from 1st Market Expansion Re-Pricing of Ultomiris, Soliris
May 16, 2024
- BMS’s Sotyktu to Get 8.6% Price Cut in August after Cost-Effectiveness Assessment
May 16, 2024
- Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
May 15, 2024
- Japan Will Hew to 4-Minister Pact on Off-Year Revisions: Health Minister
May 15, 2024
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- Simplified Delisting to Be Allowed for Generics with Low Market Share from September: MHLW
May 13, 2024
- Posaconazole Added to List of Azole Antifungals Contraindicated for Xarelto on Bleeding Risks
May 13, 2024
- Shionogi COVID Jab Up for PAFSC Review Again after Efficacy Questions; Pfizer’s Zavicefta and Lots More on Roster
May 13, 2024
- Apply Elective Care Scheme to Original Biologics with Biosimilars: Professor to LDP
May 10, 2024
- Jaypirca, Prevymis Sail Through MHLW Panel Review; Avigan’s SFTS Use on Hold
May 10, 2024
- Researchers Urge Japan to Help Develop Domestic CAR-T Therapies
May 9, 2024
- Japan Needs Special Law on Medical Data to Allow Access Without Patient Consent: JPMA
May 8, 2024
- New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
- H5N1 Pre-Pandemic Flu Vaccine Selected for Stockpiling in FY2024
May 7, 2024
- Diagnostics of Original Biologics Can Be Used for Biosimilars Too: MHLW
May 7, 2024
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…